ESBL and Carbapenem-Resistant Gram-Negatives
On this page
Direct answer
ESBL-producing Enterobacterales are Gram-negative bacilli that hydrolyse penicillins, third-generation cephalosporins and aztreonam but spare carbapenems. Carbapenem resistance means the isolate has also lost susceptibility to meropenem or imipenem, most often through a carbapenemase enzyme, which leaves few reliable options. Carbapenems remain the treatment of choice for serious ESBL infections, and piperacillin-tazobactam is not a reliable substitute.
What you must remember
- ESBL genes: Mostly plasmid-borne, with CTX-M the commonest family worldwide; clavulanate and tazobactam inhibit them.
- Carbapenemase classes: KPC is class A, NDM, VIM and IMP are class B metallo-beta-lactamases, and OXA-48-type enzymes are class D.
- Metallo-beta-lactamases: Zinc-dependent enzymes that escape clavulanate, tazobactam and avibactam but spare aztreonam.
- Indian context: NDM-1 was first described in a Klebsiella isolate from a patient who had been treated in India, and NDM producers are now widely reported across the subcontinent.
- Serious ESBL infection: Meropenem is the drug of choice, with ertapenem an option only when the patient is stable.
- Last-line agents: Colistin, tigecycline, fosfomycin for selected urinary infection, ceftazidime-avibactam for KPC and OXA-48 producers, and cefiderocol in specialist settings.
A stepwise approach to a resistant bloodstream infection
Consider a 58-year-old diabetic admitted with urosepsis after a catheter change. The urine grows Escherichia coli resistant to ceftriaxone and ceftazidime, and the report also shows piperacillin-tazobactam susceptibility, which tempts the team to keep a penicillin.
- Confirm an ESBL: A clavulanate double-disc synergy test confirms an ESBL.
- Switch to a carbapenem: The team switches to a carbapenem once bacteraemia is established.
- Remove the source: The catheter is removed and any obstructed kidney is drained.
- Step down carefully: Oral step-down follows only after clinical stability and a susceptible isolate.
- Reassess on day three: Reassessment, with repeat cultures where the source is uncertain, decides whether the regimen continues or changes.
- Control infection in parallel: Carbapenemase producers are a priority for contact precautions and screening of ward contacts.
If the isolate were instead a meropenem-resistant Klebsiella pneumoniae, an EDTA-disc synergy result would suggest a metallo-beta-lactamase, making ceftazidime-avibactam alone unhelpful. The team would then consider aztreonam with avibactam, which protects aztreonam from co-produced ESBL or AmpC enzymes, usually in a specialist centre. Colistin may be added according to susceptibility (tigecycline is unreliable in bloodstream infection because of low serum levels), with daily creatinine and neurological checks during colistin therapy.
Where the exam tries to catch you
Four traps recur on this topic.
- Trap: assuming clavulanate or tazobactam rescues a carbapenemase producer Correct: clavulanate inhibits ESBLs but not NDM, so the enzyme class must be checked against any reassuring combination.
- Trap: choosing cefepime for serious ESBL infection Correct: cefepime is more stable against many ESBLs than third-generation cephalosporins, yet current guidance still prefers a carbapenem for serious infection.
- Trap: using aztreonam without considering co-produced enzymes Correct: metallo-beta-lactamases do not hydrolyse aztreonam, but co-produced ESBL or AmpC enzymes do, which is why avibactam is added.
- Trap: equating carbapenem resistance with pan-resistance Correct: carbapenem-resistant does not mean pan-resistant, so colistin or tigecycline susceptibility must be read on the report.
In Acinetobacter baumannii the logic changes, because sulbactam has intrinsic activity.
Frequently asked questions
Which laboratory test points to a metallo-beta-lactamase producer?
An EDTA-disc synergy test, in which a carbapenem disc sits beside an EDTA-containing disc, is the usual screen; a synergy zone toward the EDTA disc suggests a metallo-beta-lactamase. Molecular or immunochromatographic tests then identify the exact enzyme, such as NDM, VIM or IMP.
Is piperacillin-tazobactam acceptable for ESBL bacteraemia?
Piperacillin-tazobactam is not a reliable substitute for a carbapenem in bloodstream infection caused by ESBL-producing Enterobacterales, even when the report shows susceptibility. Carbapenems are preferred for serious ESBL infection because their activity against these enzymes is more predictable.
Why is colistin used against carbapenem-resistant Gram-negatives and what must be monitored?
Colistin, a polymyxin, remains active against many carbapenem-resistant Enterobacterales and Acinetobacter baumannii when other options are unavailable, and it is usually given in combination. Its main toxicities are nephrotoxicity and neurotoxicity, so serum creatinine, urine output and neurological status need close monitoring throughout the course.
Does avibactam work against NDM producers?
No. Avibactam inhibits serine enzymes such as KPC, AmpC and OXA-48, but it does not inhibit NDM, which is a metallo-beta-lactamase. Ceftazidime-avibactam is therefore unreliable against NDM producers, and aztreonam combined with avibactam is used instead in specialist centres.